Q3 EPS Forecast for Perspective Therapeutics Lifted by Analyst

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Analysts at Brookline Capital Markets boosted their Q3 2026 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a research report issued on Tuesday, August 11th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will post earnings of ($0.25) per share for the quarter, up from their previous estimate of ($0.32). The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($1.07) per share. Brookline Capital Markets also issued estimates for Perspective Therapeutics’ Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($0.99) EPS and Q4 2027 earnings at ($0.32) EPS.

A number of other equities research analysts have also recently commented on the stock. BTIG Research reaffirmed a “buy” rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Piper Sandler lowered their price target on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday. Finally, Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, May 5th. Eight analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $12.38.

Perspective Therapeutics Stock Down 4.9%

NYSEAMERICAN:CATX opened at $3.10 on Friday. The firm’s fifty day moving average is $3.08 and its two-hundred day moving average is $3.94. Perspective Therapeutics has a one year low of $1.96 and a one year high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. Perspective Therapeutics had a negative return on equity of 44.22% and a negative net margin of 28,467.97%.The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.09 million.

Institutional Trading of Perspective Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth approximately $28,000. Russell Investments Group Ltd. increased its stake in Perspective Therapeutics by 184.1% during the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after acquiring an additional 5,475 shares during the last quarter. nVerses Capital LLC purchased a new stake in Perspective Therapeutics in the fourth quarter valued at $31,000. AXQ Capital LP lifted its stake in shares of Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after purchasing an additional 2,481 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new position in shares of Perspective Therapeutics during the 4th quarter worth $35,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics News Roundup

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Brookline raised its 2026 EPS forecasts: The firm now expects a loss of $0.25 per share in Q3 2026, $0.26 in Q4 2026 and $0.99 for full-year 2026, compared with previous estimates of $0.32, $0.36 and $1.23, respectively. Smaller projected losses are a positive earnings revision and may support CATX shares.
• Positive Sentiment: Q4 2027 loss forecast issued: Brookline expects Perspective Therapeutics to report a $0.32-per-share loss in Q4 2027, providing investors with updated longer-term estimates.
• Neutral Sentiment: 2027 estimates remain loss-making: Brookline forecasts losses of $0.26 per share in Q1 2027, $0.27 in Q2, $0.30 in Q3 and $1.14 for full-year 2027. These forecasts suggest continued operating losses and do not indicate near-term profitability.
• Negative Sentiment: Piper Sandler lowered its expectations for the stock price: The price-target or valuation change signals a less favorable view of Perspective Therapeutics and could weigh on investor sentiment. Piper Sandler Has Lowered Expectations for Perspective Therapeutics Stock Price

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.